Rob Maloney: What If Hemophilia No Longer Needed Lifelong Treatment?
Rob Maloney, Chief Executive Officer of Hemophilia of Georgia, shared a post on LinkedIn:
“I’ve said something a few times that usually gets a laugh, but I mean it.
I’d like to work myself out of a job.
Here’s what I mean. I would love to see the day when hemophilia treatment has advanced so far that what we currently build entire systems around becomes far less necessary.
A real cure.
Or something close to it.
Not just symptom management stretched out over a lifetime.
I think we could be closer than people realize.
And I want Hemophilia of Georgia to be part of helping push that future forward.
That means supporting research, advocating for investment in research, and helping connect our community to opportunities that advance care.
Right now, a lot of the innovation in healthcare still centers on managing chronic conditions, not eliminating them.
That may be practical. But as a mission-driven leader, I’m interested in something else.
What if the next decade could fundamentally change how a person with hemophilia lives?
What if families no longer had to choose where to live based on proximity to a treatment center?
What if a child in South Georgia could grow up without needing the same level of medical caution because the underlying condition had been changed at the root?
Even in a future with transformative therapies, families will still need education, advocacy, community, and support.
But the burdens they face could look very different than they do today.
I’m proud of the support systems we’ve built. I believe deeply in the work HoG does every day.
But if we can support the kind of research that makes our current model less necessary over time, then that’s not a threat to the mission.
That is the mission.
If leadership is stewardship, then part of my job is not just maintaining what we’ve inherited.
It’s helping build a future where families need less rescue and more freedom.”
Other posts featuring Rob Maloney on Hemostasis Today.
-
Jul 22, 2026, 05:26Richard Dalyai: Can AI Safely Refill Medications?
-
Jul 22, 2026, 05:15Annie Bauzon: What Is Anemia? – Microcytic, Normocytic and Macrocytic Types Explained
-
Jul 22, 2026, 05:01Melina Rodriguez: First FDA-Approved VWD Prophylaxis for All Ages
-
Jul 22, 2026, 04:59Martina Wolff: Advancing Knowledge Through Global Collaboration at ISTH 2026
-
Jul 22, 2026, 04:52G. Shellye Horowitz: Hemophilia A Genetics – Hemophilia A and Pregnancy
-
Jul 21, 2026, 23:43Shadi Tabibian: The Clinical Power of Patient Stories in Rare Bleeding Disorders
-
Jul 21, 2026, 23:35Pete Stibbs: Impressed with PE Compass and Clinical Compass from Mona Ranade and Team
-
Jul 21, 2026, 23:28Toby Richards: Important Announcement about Testing for Iron Deficiency
-
Jul 21, 2026, 21:12Ammar Al Awawdeh: Bridging the Hemostatic Gap – Functional Platelet Salvage in CPB